Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Ausanil®, A New Non-Prescription Severe Headache And Migraine Treatment, Is Now Available To Provide Rapid Pain Relief Without Systemic Side Effects Or Drug Interactions

Developed by a Neurologist to Treat His Own Migraines, Ausanil Homeopathic Nasal Spray Is Now Available to Headache Sufferers Nationwide


News provided by

VR1, Inc.

Mar 25, 2014, 09:45 ET

Share this article

Share toX

Share this article

Share toX

NEW YORK, March 25, 2014 /PRNewswire/ -- VR1, Inc. announces the availability of Ausanil®, a new non-prescription homeopathic nasal spray specifically formulated by neurologist and VR1 founder Dr. Anjan Chatterjee to provide rapid pain relief from severe headaches and migraines with no reported systemic side effects or adverse drug-drug interactions. Achieving rapid pain relief is a significant challenge for millions of people with headaches and migraine, one of the top 10 most disabling conditions in the U.S.

Continue Reading
Ausanil, non-prescription homeopathic severe headache and migraine nasal spray (www.ausanil.com). (PRNewsFoto/VR1, Inc.) (PRNewsFoto/VR1, INC.)
Ausanil, non-prescription homeopathic severe headache and migraine nasal spray (www.ausanil.com). (PRNewsFoto/VR1, Inc.) (PRNewsFoto/VR1, INC.)

"We are pleased to offer Ausanil as an important new option for severe headache and migraine patients still searching for a treatment that is effective, safe and accessible," said lifelong migraine sufferer Dr. Chatterjee. "As a physician who has treated thousands of headache patients, and as a lifelong migraine sufferer myself, I know how frustrating and debilitating it can be when you are unable to function in your daily life because you have to wait so long for your medication to take effect."

Approximately one-third of the 36 million migraine sufferers in the U.S. are not satisfied with their current treatment regimen. Ausanil was developed to address several of the biggest challenges for millions of sufferers, including inadequate pain relief and side effect limitations.

Dr. Chatterjee drew from decades of direct patient care and extensive experience in neuroscience drug development to develop Ausanil. Specifically formulated to provide rapid relief, when used as directed, Ausanil can be taken multiple times per day, alone or with other migraine medications, without reported risk of systemic side effects or drug-drug interactions. Ausanil is non-habit forming and does not contain caffeine, zinc, aspirin or acetaminophen. Dr. Chatterjee uses Ausanil to successfully treat his own migraines, achieving pain relief within a matter of minutes.

An Unmet Medical Need

Many current treatments for severe headaches and migraine have limitations for many patients due to a variety of factors, including: onset of effect (some medications require up to an hour or more to achieve significant effect), side effects (such as gastrointestinal ulcers, liver damage and risk of dependence), and potential adverse interactions with other medications, including antidepressants and blood thinners. Certain treatments may also be contraindicated for those with heart disease or a family history of heart disease or diabetes.

American Headache Society guidelines generally advise against using prescription therapies, specifically opioids, as first-line treatment for migraine due to risk of dependency. The guidelines also warn that commonly used over-the-counter (OTC) pain relievers should not be used more than twice weekly due to an increase in "medication overuse headache" as well as potential liver, kidney and stomach issues.

"Severe headaches and migraine represents a significant unmet medical need as there are few new treatment options available to sufferers to help them get back to their lives quickly when pain strikes," said Dr. Chatterjee. "As a safe, homeopathic product, Ausanil does not pose the common challenges patients can face, such as debilitating side effects, drug-drug interactions and contraindications for specific conditions including heart, kidney and liver disease."

Most users have reported rapid pain relief with Ausanil. Individual experience will vary.

How Ausanil Works

Ausanil works by acting locally on a receptor on the sensory nerve cells in the nose to ultimately reduce pain. When administered, a local stinging sensation in the nasal cavity indicates the sensory nerve has been stimulated, which leads to a reduction in the release of pain molecules in the brain. It is believed that this decrease in pain molecules leads to a reduction in swelling and inflammation of blood vessels surrounding the brain, resulting in pain relief. Ausanil treatment acts locally in the nose and only small quantities are needed for rapid pain relief, so that it does not interact with other medications and can be taken as often as needed. For more details on how Ausanil works to relieve headache pain, visit http://ausanil.com/learn-more/.

Ausanil is now available without prescription at Ausanil.com and Amazon.com and retails for $28.95 per bottle plus tax and shipping. Each bottle contains approximately 50 doses, less than $.60 per dose.

To learn more about Ausanil and how it works, Dr. Anjan Chatterjee, and migraine and severe headaches, visit www.ausanil.com.

About Migraine
Migraine is a debilitating condition that causes intense pulsing or throbbing pain typically on one side of the head along with associated symptoms, such as nausea and/or vomiting or sensitivity to both light and sound. Migraine ranks in the top 10 of the world's most disabling medical conditions with nearly 36 million sufferers in the U.S. alone, including people of all ages. Migraine is three times more common in women than men, and affects nearly 30 percent of women over a lifetime. More than 90 percent of sufferers are unable to work or function normally during their migraine attacks. Direct medical costs and indirect costs of migraine, including millions of missed work days and lost productivity, can run up to approximately $29 billion a year in the U.S.

About Ausanil
Ausanil was developed as a non-prescription homeopathic nasal spray treatment to provide rapid relief from severe headache and migraine pain. When used in accordance with directions, Ausanil is safe to use several times daily without systemic side effects or adverse drug interactions. Ausanil may also be an effective treatment option for cluster headaches, chronic daily headaches, frequent tension headaches and medication overuse headaches.

Specifically formulated for severe headaches and migraines, Ausanil should not be used for mild or infrequent headaches, sinus headaches, atypical migraines, basilar migraines, migraines with abdominal symptoms, or any new onset severe headaches that are unusual for the sufferer. New onset headaches that are severe and come on suddenly require immediate medical attention. Ausanil should not be used in people with an active nasal infection, active and symptomatic asthma or upper respiratory tract infection, or with a severely deviated nasal septum. Ausanil is not recommended for women who are pregnant or breastfeeding, or for patients under age 18. People allergic to any of the listed ingredients should not use Ausanil.

While Ausanil is available without a prescription, it's important that patients always discuss using Ausanil and its incorporation into their current treatment regimens with their doctors.

About Dr. Anjan Chatterjee
Board certified in Neurology and Psychiatry, Dr. Chatterjee has more than two decades of direct patient care experience, treating patients with a wide variety of neurological and psychiatric disorders. Over the last decade, Dr. Chatterjee has worked at Merck Research Labs and Pfizer to develop neuroscience medicines. He has presented peer reviewed research at multiple medical conferences in the U.S. and across Europe and has authored multiple research manuscripts published in peer reviewed medical journals, including Movement Disorders, Headache, Cephalalgia, Journal of Neurology Neurosurgery and Psychiatry, Biological Psychiatry, Journal of Clinical Psychopharmacology and the American Journal of Psychiatry. He is also a reviewer for several peer reviewed medical journals, including Neurobiology of Disease, Journal of Neurology Neurosurgery and Psychiatry, Psychiatry Research and Movement Disorders. He is a member of several professional organizations, including the American Academy of Neurology (AAN), American Headache Society (AHS), Movement Disorders Society (MDS), American Psychiatric Association (APA), American Medical Association (AMA) and American Association of Family Practice Physicians (AAFP). Dr. Chatterjee graduated Medical School from the University of Delhi, India, earned a Master's in Public Health (Epidemiology and Biostatistics) from Columbia University, and has a Master of Business Administration from Columbia Business School.

About VR1, Inc.  
VR1 is committed to meeting the needs of patients by providing therapeutic solutions that are effective, safe and accessible. Founded by neurologist Dr. Anjan Chatterjee, VR1 focuses on providing treatments to address acute pain associated with migraine and other severe headache conditions.

Related Links
Ausanil Twitter Page 
Ausanil YouTube Page 
Ausanil Facebook Page 
Ausanil Website

Video - http://www.youtube.com/watch?v=N9tW2pTp0Fk
Photo - http://photos.prnewswire.com/prnh/20140325/MM89227 
Ausanil Fact Sheet - http://origin-qps.onstreammedia.com/origin/multivu_archive/ENR/FX-20140324-MM89227-PDF.pdf

SOURCE VR1, Inc.

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.